- Home
- AVIR vs CHPT Comparison
AVIR vs CHPT Comparison
Compare AVIR & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- CHPT
- Stock Information
- Founded
- AVIR 2012
- CHPT 2007
- Country
- AVIR United States
- CHPT United States
- Employees
- AVIR N/A
- CHPT N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- CHPT Industrial Specialties
- Sector
- AVIR Health Care
- CHPT Consumer Discretionary
- Exchange
- AVIR Nasdaq
- CHPT Nasdaq
- Market Cap
- AVIR 290.4M
- CHPT 256.9M
- IPO Year
- AVIR 2020
- CHPT N/A
- Fundamental
- Price
- AVIR $3.25
- CHPT $9.33
- Analyst Decision
- AVIR Hold
- CHPT Hold
- Analyst Count
- AVIR 1
- CHPT 11
- Target Price
- AVIR $6.00
- CHPT $18.40
- AVG Volume (30 Days)
- AVIR 353.8K
- CHPT 405.1K
- Earning Date
- AVIR 11-12-2025
- CHPT 12-03-2025
- Dividend Yield
- AVIR N/A
- CHPT N/A
- EPS Growth
- AVIR N/A
- CHPT N/A
- EPS
- AVIR N/A
- CHPT N/A
- Revenue
- AVIR N/A
- CHPT $397,731,000.00
- Revenue This Year
- AVIR N/A
- CHPT N/A
- Revenue Next Year
- AVIR N/A
- CHPT $12.67
- P/E Ratio
- AVIR N/A
- CHPT N/A
- Revenue Growth
- AVIR N/A
- CHPT N/A
- 52 Week Low
- AVIR $2.46
- CHPT $8.55
- 52 Week High
- AVIR $4.02
- CHPT $30.00
- Technical
- Relative Strength Index (RSI)
- AVIR 55.27
- CHPT 36.05
- Support Level
- AVIR $3.18
- CHPT $9.57
- Resistance Level
- AVIR $3.27
- CHPT $10.35
- Average True Range (ATR)
- AVIR 0.09
- CHPT 0.49
- MACD
- AVIR 0.00
- CHPT -0.19
- Stochastic Oscillator
- AVIR 60.00
- CHPT 1.46
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.